CLSN - Celsion Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

2.29

+0.01 (+0.44%)

At close: 3:59PM EDT

Stock chart is not supported by your current browser

Previous Close	2.28
Open	2.31
Bid	2.10 x 100
Ask	2.35 x 100
Day's Range	2.28 - 2.35
52 Week Range	0.22 - 6.06
Volume	91,356
Avg. Volume	234,853

Market Cap	40.625M
Beta	1.01
PE Ratio (TTM)	N/A
EPS (TTM)	-2.72
Earnings Date	May 18, 2017 - May 19, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	9.00

Trade prices are not sourced from all markets

All

News

Press Releases

ACCESSWIRE2 days ago
Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Egalet Corp. (NASDAQ: EGLT). The Company posted its financial results on March 12, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Company's quarterly total revenues grew on a y-o-y basis to outshine market forecasts.
GlobeNewswire10 days ago
International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
LAWRENCEVILLE, N.J., April 12, 2018-- Celsion Corporation, an oncology drug development company, today announced a presentation and discussion of ThermoDox ®, its proprietary heat-activated liposomal encapsulation ...
GlobeNewswire13 days ago
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Blinded Progression-Free Survival Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study. ThermoDox ®- Highlighted Symposium,“ Emerging Horizons ...
Thomson Reuters StreetEvents25 days ago
Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT
Q4 2017 Celsion Corp Earnings Call
GlobeNewswire26 days ago
Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and an Advancing Clinical Pipeline. Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT. LAWRENCEVILLE, N.J., ...
ACCESSWIRE26 days ago
Celsion Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 27, 2018 / Celsion Corporation (NASDAQ: CLSN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 27, 2018, at 11:00 AM Eastern Time. ...
Simply Wall St.26 days ago
When Will Celsion Corporation (NASDAQ:CLSN) Become Profitable?
Celsion Corporation’s (NASDAQ:CLSN): Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.Read More...
GlobeNewswirelast month
Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
LAWRENCEVILLE, N.J., March 20, 2018-- Celsion Corporation announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2017 and provide an update ...
GlobeNewswirelast month
Celsion Corporation to Present at Upcoming Investor Conferences
LAWRENCEVILLE, N.J., March 12, 2018---- Celsion Corporation, an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer, will present at ...
GlobeNewswirelast month
New Research Coverage Highlights Gastar Exploration, CENTENNIAL RES, Advance Auto Parts, Celsion, Regions Financial, and Abraxas Petroleum — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, March 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
GlobeNewswire2 months ago
Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
LAWRENCEVILLE, N.J., March 05, 2018-- Celsion Corporation today announced that Premal H. Thaker, M.D., M.S., Associate Professor of Obstetrics and Gynecology at the Siteman Cancer Center at the Washington ...
GlobeNewswire2 months ago
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting
LAWRENCEVILLE, N.J., Feb. 12, 2018-- Celsion Corporation today announced that an abstract discussing the Company’ s Phase III HEAT study evaluating ThermoDox ® in combination with radiofrequency ablation ...
Zacks4 months ago
Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
InvestorPlace4 months ago
FDA Win Sends Celsion Corporation (CLSN) Shares Higher
The U.S. Food and Drug Administration (FDA) has approved the company’s plans to initiate its OVATION II Study for a DNA-based immunotherapy that’s designed to locally treat ovarian cancer called GEN-1. The company’s Medical Advisory Board helped to develop the Phase I/II trial for Celsion’s drug. The upcoming Phase I/II study from Celsion will begin with a single dose escalation to a higher dose than before in order to help determine what a safe and tolerable dose of the treatment would be, including the study of how an immune system responds to such a dose.
Zacks4 months ago
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
SmarterAnalyst4 months ago
Celsion Corporation (CLSN) Shares on the Rise; Here’s Why
Celsion Corporation (NASDAQ:CLSN) investors have a smile on their faces Thursday morning, after the tiny drug maker won FDA clearance for OVATION II Study, the Company’s planned Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion CEO Michael H. Tardugno added, "GEN-1 holds the potential for tremendous promise as a cancer treatment in the rapidly emerging area of immunotherapy.
Zacks4 months ago
5 Breakout Stocks Offering Terrific Returns
If properly implemented, such a strategy could deliver impressive returns.
Capital Cube4 months ago
ETFs with exposure to Celsion Corp. : January 2, 2018
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube5 months ago
ETFs with exposure to Celsion Corp. : November 30, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
SmarterAnalyst5 months ago
Here’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer
Celsion Corporation (NASDAQ:CLSN) investor sentiment is getting stoked today on back of new bullish attention from Oppenheimer analyst Hartaj Singh. Even though this biotech company has drawn some critical fire circling lead program in ThermoDox in liver cancer, what has Singh making a strong bullish case for "OPTIMA(L) redemption?"